The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting [PDF]
Cancer Management and Research, 2015 Swetha Rao Palli,1 Michael Grabner,1 Ralph A Quimbo,1 Hope S Rugo2 1HealthCore, Wilmington, DE, 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA Purpose: To determine the incidence of ...
Palli SR, Grabner M, Quimbo RA, Rugo HS
doaj +4 more sources
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study [PDF]
BMC Health Services Research, 2012 Background 1st generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs), and palonosetron, a 2nd generation 5-HT3 RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) associated with moderately (MEC) and ...
Lin Swu-Jane +4 more
doaj +2 more sources
A Case of Possible Infusion-Related Reactions Caused by Palonosetron [PDF]
Case Reports in OncologyIntroduction: An infusion-related reaction (IRR) is an adverse event that typically occurs when cytotoxic drugs or monoclonal antibodies are administered.
Toru Kadono +4 more
doaj +2 more sources
Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a systematic review and meta-analysis [PDF]
Journal of Minimally Invasive SurgeryPurpose: Postoperative nausea and vomiting (PONV) is a prevalent and distressing complication, especially in laparoscopic surgeries. This review compares the efficacy and safety of palonosetron and ondansetron in preventing PONV after laparoscopic ...
Jitendra Kumar +11 more
doaj +2 more sources
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting [PDF]
Korean Journal of Anesthesiology, 2014 BackgroundThe efficacy of palonosetron in preventing postoperative nausea and vomiting (PONV), as well as chemotherapy-induced nausea and vomiting, has already been demonstrated in multiple clinical studies.
Ji Won Kang, Soo Kyoung Park
doaj +1 more source
Analgesic effects of palonosetron in the intravenous propofol injection [PDF]
Korean Journal of Anesthesiology, 2014 BackgroundPropofol is a good induction agent, but it has the disadvantage of causing pain on intravenous injection. The incidence of propofol-induced pain is approximately 70%.
Han-Bom Ryu, Su-Jin Kim
doaj +1 more source
The effect of palonosetron on rocuronium-induced withdrawal movement
Brazilian Journal of Anesthesiology, 2017 Background: Rocuronium causes pain and withdrawal movement during induction of anesthesia. In this study, palonosetron was investigated to have analgesic effect on the reduction of rocuronium-induced withdrawal movement.
Ki-Bum Park +5 more
doaj +3 more sources
The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting [PDF]
Korean Journal of Anesthesiology, 2012 Background5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are effective and safe on postoperative nausea and vomiting (PONV). Palonosetron, the newest 5-HT3 antagonist, has potent antiemetic property.
Jung Woo Park +7 more
doaj +1 more source
Journal of Medical Science, 2023 Background. Propofol is widely used for induction, maintenance of anaesthesia and possess many characteristics of an ideal intravenous anaesthetic agent. It is known to cause severe, sharp, stinging or burning pain on injection which is considered to be
Nethra Surhonne +2 more
doaj +1 more source